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Abstract
Background: Plant viruses can be employed as versatile vectors for the production of vaccines by
expressing immunogenic epitopes on the surface of chimeric viral particles. Although several
viruses, including tobacco mosaic virus, potato virus X and cowpea mosaic virus, have been
developed as vectors, we aimed to develop a new viral vaccine delivery system, a bamboo mosaic
virus (BaMV), that would carry larger transgene loads, and generate better immunity in the target
animals with fewer adverse environmental effects.
Methods: We engineered the BaMV as a vaccine vector expressing the antigenic epitope(s) of the
capsid protein VP1 of foot-and-mouth disease virus (FMDV). The recombinant BaMV plasmid
(pBVP1) was constructed by replacing DNA encoding the 35 N-terminal amino acid residues of the
BaMV coat protein with that encoding 37 amino acid residues (T128-N164) of FMDV VP1.
Results: The pBVP1 was able to infect host plants and to generate a chimeric virion BVP1
expressing VP1 epitopes in its coat protein. Inoculation of swine with BVP1 virions resulted in the
production of anti-FMDV neutralizing antibodies. Real-time PCR analysis of peripheral blood
mononuclear cells from the BVP1-immunized swine revealed that they produced VP1-specific IFN-
γ. Furthermore, all BVP1-immunized swine were protected against FMDV challenge.
Conclusion: Chimeric BaMV virions that express partial sequence of FMDV VP1 can effectively
induce not only humoral and cell-mediated immune responses but also full protection against
FMDV in target animals. This BaMV-based vector technology may be applied to other vaccines that
require correct expression of antigens on chimeric viral particles.
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Background
Foot-and-mouth disease virus (FMDV) is the etiological
agent of foot-and-mouth disease (FMD) that infects clo-
ven-hoofed animals such as pigs, sheep and cattle and
causes serious damage in the livestock industry [1].
Although conventional vaccines based on the chemically
inactivated virus are effective against FMDV [2], outbreaks
of FMD sometimes result from virus escaping from vac-
cine production units or from the use of improperly inac-
tivated virus [2-4]. Alternative approaches to produce an
effective and safe FMD vaccine are needed to replace inac-
tivated virus-based vaccines.
FMDV particles are composed of 60 copies of each of four
capsid proteins termed VP1, VP2, VP3 and VP4, which are
cleavage products of the capsid precursor polypeptide
P1[5,6]. VP1, VP2 and VP3 form the outer capsid shell,
whereas VP4 lines the interior surface [7]. Among these
capsid proteins, VP1 contains the major antigenic
domains of the virus [8-11], with its G-H loop including
at its apex a highly conserved Arg-Gly-Asp (RGD) tripep-
tide, which can bind to integrins and facilitate the inter-
nalization of FMDV into target cells [12,13]. Therefore,
many investigators have used VP1 as a candidate vaccine
against FMDV [10].
Chimeric plant virus-derived vaccines against FMD have
been described and used in experimental or natural hosts
[14-16]. Cowpea mosaic virus (CPMV) expressing VP1
epitopes on the surface of the virus was first reported to
react with FMDV-specific antiserum [14]. Tobacco mosaic
virus (TMV) expressing the full VP1 protein or an epitope
of VP1 was subsequently shown to induce protective
immunity against FMDV in both mice and swine [15,16].
Although preliminary protection against FMDV in swine
was demonstrated with TMV expressing the VP1 epitope
[16], effort is needed to improve not only the replication
efficiency and stability of such chimeric viruses but also
the immune responses they induce [17].
Recently, potato virus X (PVX), a member of the Potexvirus
genus, was reported to be an effective epitope presenta-
tion system for chimeric virus particle production [18-21].
Analysis by fiber diffraction pattern has shown that the
surface features of PVX are more flexible than those of
TMV [22], which likely contributes significantly to the
accommodation of foreign peptides on the surface of the
virus. Bamboo mosaic virus (BaMV) is also a flexuous rod-
shaped member of the Potexvirus genus. It infects both
monocotyledonous and dicotyledonous plants [23]. The
viral genome of BaMV consists of a single-stranded posi-
tive-sense RNA molecule with a 5' cap structure and 3'
poly(A) tail that contains five major open reading frames
(ORFs) encoding different target proteins for viral replica-
tion, movement and assembly [24-27]. The ORF5 encodes
a coat protein (CP) for virus encapsidation, cell-to-cell
and long-distance movement [24].
Here we describe generation of a recombinant BaMV-
based vector, namely pBVP1, by replacing complementary
DNA (cDNA) encoding 35 amino acid residues from the
N-terminal sequence of BaMV CP with cDNA encoding 37
amino acid residues (T128-N164) of FMDV (O/Taiwan/97)
VP1. We examined the ability of this recombinant viral
vector to generate a chimeric BaMV virus in plants and the
effectiveness of the chimeric virus to induce immune
responses and protection of swine against FMDV chal-
lenge.
Methods
Construction of an recombinant infectious pBVP1 vector
The full-length infectious cDNA of BaMV-S with an
upstream cauliflower mosaic virus 35S promoter
sequence was cloned in the plasmid pUC119 (Fig. 1a) as
described previously [27]. A vector pBS-d35CP was
derived from the aforementioned pBaMV-S plasmid by
deletion of the N-terminal 35 amino acid sequence of CP
and insertion of multiple cloning sites (AgeI-NheI-NotI)
by PCR (Fig. 1b). A sequence corresponding to amino
acids 128–164 of VP1 of FMDV serotype O/Taiwan/97
was inserted into pBS-d35CP by PCR with the plasmid
pVP1/Q15 used as a template [28]. The primers used were
pr128164N (5'-GGgctagcAccatggACACCGTCTACAACG-
GGAG-3'; the sequence in small letters represents the
sequentially ordered NheI and NcoI sites; the NcoI recog-
nition sequence provided an AUG initiation codon) and
pr128164C (5'-TTgcggccgcGTTGAAGGAGGTAGGC-3';
the sequence in small letters represents a NotI site). PCR
was carried out at an initial temperature of 94°C for 5 min
followed by 25 cycles of 94°C for 30 s, 50°C for 30 s and
an extension at 72°C for 30 s. The amplified fragment
encoding VP1 peptide was purified, sequenced and
cloned into plasmid pBS-d35CP at the NheI and NotI sites.
The sequence of the new plasmid was confirmed and
denoted as pBVP1 (Fig. 1c).
Virus propagation and purification
Plants of the local lesion host Chenopodium quinoa (C. qui-
noa) and systemic host Nicotiana benthamiana (N. bentha-
miana) were grown in a greenhouse exposed to normal
daylight. For the infectivity assay, approximately 1 μg of
purified viral DNA plasmids in 10 μl of double-distilled
H2O was used to inoculate each leaf of test plants at the 6-
leaf stage [27]. Observations for local lesions took place
10 days post-inoculation. For antigen preparation, 8 to 10
fully expanded leaves of C. quinoa plants that had been
inoculated with pBaMV-S or pBVP1 were harvested at 10
days post-inoculation. The virions were subsequently
purified from the leaves and the yield was determined by
ultraviolet absorption as described previously [29]. TheBMC Biotechnology 2007, 7:62 http://www.biomedcentral.com/1472-6750/7/62
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amount of VP1 epitope expressed in the chimeric virus
BVP1 was estimated at about 14.3% of the total viral coat
proteins. Purified virions were dissolved in BE buffer (10
mM Borate, pH 9.0, 1 mM EDTA), then stored at -20°C
for subsequent immunization of swine.
Western blotting analysis and immunogold labeling of virus 
particles
Rabbit anti-FMDV VP1 serum was prepared as described
previously [28]. Total proteins were prepared from mock
or viral DNA plasmid-inoculated C. quinoa with use of 1:2
(w/v) extraction buffer (50 mM Tris-HCl, pH 8.0, 10 mM
KCl, 10 mM MgCl2, 1 mM EDTA, 20% glycerol and 2%
SDS) and heated at 100°C for 5 min. Protein samples
were separated by 12% SDS-PAGE and electrophoretically
transferred to Immobilon-P membranes (Bio-Rad) with
200 mA for 1 h at 4°C. After blocking, the proteins on the
membranes were probed with anti-BaMV-S CP or anti-
FMDV VP1 antibodies or serum from FMDV-infected
swine and then processed as described previously [27].
For immunogold labeling of virus particles, the pBaMV-S
or pBVP1-inoculated leaves of C. quinoa were harvested at
10 days post-inoculation and the labeling procedures
were conducted as described previously [30]. Briefly, grids
were first floated on leaf extract for 5 min followed by
diluted 1:100 anti-BaMV-S CP or anti-FMDV VP1 antibod-
ies and then decorated by gold-labeled goat anti-rabbit
IgG complexes. The grids were then stained with 2% ura-
nyl acetate and examined under a Philips CM100 electron
microscope.
Analysis of the purity of BVP1 virions on SDS-PAGE
The recombinant virus BVP1 was purified from infected
leaves and electrophoresed on a 12.5% polyacrylamide
gel containing 1% SDS. The gel was stained with PlusOne
Silver Staining Kit (Amersham Bioscience, Sweden).
Immunization and viral challenge in swine
Specific pathogen-free female or castrated male swine (2
months old, weighing approximately 25 kg) were
obtained in Taiwan. In experiment 1, two groups of three
pigs each were immunized respectively by intramuscular
injection into the neck muscles beside the ears with 10 mg
and 5 mg of BVP1 virions emulsified with Montanide ISA
206 (Seppic, France) at a 1:1 ratio (v/v). In addition, two
pigs were immunized with wild-type virus BaMV-S emul-
sified with Montanide ISA 206 and another two with ster-
ile PBS buffer as negative control groups. All animals
boosted with the same amount six weeks later. Sera were
collected for analysis from the immunized animals at days
0, 28, 42, 56, and 70. Four weeks after boost, all swine
were challenged with 0.5 ml of 105.0 TCID50 of FMDV O/
Taiwan/97 by subcutaneous injection into the right front
heel bulb. The swine were monitored daily for FMD symp-
toms for 14 days. Signs of FMD symptoms included ele-
vated body temperature above 40°C for 3 successive days,
lameness, vesicular lesions on the snout, and coronary
bands on the legs [28]. In experiment 2, three groups of
three swine each were vaccinated with 5 mg, 1 mg, and 0.5
mg BVP1 respectively and boosted at day 28 according to
the same regimen. As negative controls, two pigs were
immunized with wild-type virus BaMV-S and another two
with sterile PBS buffer. Seven days after boost (i.e., on day
35), swine were injected with 0.5 ml of 105.0 TCID50 of
FMDV (O/Taiwan/97) as in experiment 1. The viral chal-
Schematic representation of plasmids of wild-type BaMV-S as  well as recombinant pBS-d35CP and pBVP1 Figure 1
Schematic representation of plasmids of wild-type 
BaMV-S as well as recombinant pBS-d35CP and 
pBVP1. (a) pBaMV-S is an infectious BaMV cDNA plasmid 
under the control of cauliflower mosaic virus 35S promoter. 
The BaMV genome comprises 5 open reading frames (ORFs). 
The ORF1 encodes for viral replicase, whereas ORF2, ORF3 
and ORF4 are called a "Triple-gene-block" that encodes viral 
movement proteins. ORF5 (CP) encodes a structural protein 
for virion formation. (b) pBS-d35CP is a mutated BaMV plas-
mid whose DNA coding for the N-terminal 35 amino acids of 
CP has been truncated, and multiple cloning sites have been 
engineered. (c) pBVP1 is a recombinant plasmid derived from 
pBS-d35CP by inserting the DNA coding for the 37 amino 
acid VP1 peptide to replace that coding for the N-terminal 35 
amino acids of CP.BMC Biotechnology 2007, 7:62 http://www.biomedcentral.com/1472-6750/7/62
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lenge experiments were carried out in high containment
facilities.
FMDV preparation for swine challenge
The FMDV used in challenge experiments was produced
from a homogenized mixture of vesicular fluid and epi-
thelium of a pig infected with FMDV O/Taiwan/97. The
titer of the virus was titrated in BHK-21 cells in accordance
with FMD World Reference Laboratory, Pirbright, UK.
ELISA for serum titer analysis
ELISA was performed as described previously with minor
modifications [31]. In brief, 96-well microtiter plates were
coated with recombinant VP1 protein (1 μg/well) in 0.1 M
carbonate/bicarbonate buffer, pH 9.4, overnight at 4°C.
Plates were blocked with 5% skim milk in PBS and
washed three times with PBS containing 0.1% Tween-20
(PBST). Samples of 1:50 diluted serum in serial dilution
were added to wells (50 μl/well) and incubated for 1 h at
37°C. After three washings, a 1: 3000 diluted biotinylated
goat anti-swine IgG antibody was added for 1 h at 37°C.
The plates were subsequently washed, and streptavi-
din:peroxidase (1:3000 dilution) was added. After incu-
bation for 1 h at room temperature, the plates were
washed again in PBST. Enzyme substrate 3, 3', 5, 5'-
tetramethylbenzidine (Sigma) was then added, and the
colorigenic reaction was carried out at room temperature
for 10 min. Finally, an equal volume of 1 N H2SO4 was
added to stop the reaction, and the absorbance at 450 nm
was measured by an ELISA reader. The titer was defined as
the reciprocal of the dilution that resulted in an absorb-
ance value 50% of total value obtained from subtracting
maximum absorbance with background absorbance. The
maximum absorbance is the absorbance at the plateau
(around O.D. = 3.5 – 3.7) of the curve obtained by plot-
ting the optical density versus serial dilution of sera of
immunized swine in a semi-logarithmical manner.
Assay for anti-FMDV NAs
The anti-FMDV NAs assays were carried out in 96 wells
flat-bottomed plates using BHK-21 cells as described in
the OIE manual [32]. In brief, sera from test animals were
inactivated at 56°C for 30 min. Two-fold serial dilution of
sera were performed in duplicate and 50 μl of each were
added to the wells. Fifty μl of 100 TCID50 of FMDV (O/
Taiwan/97) was then added to each well. The plate was
vortexed for 1 min and incubated at 37°C for 90 min.
BHK-21 cell suspension (1 × 105cells) in EMEM contain-
ing 5% fetal bovine serum was subsequently added to
each well and incubated for 48 h. The cells were then
observed under a microscope for the cytopathic effect
(CPE) of the virus as indicated by disruption of cell mon-
olayer and change of shape from spindle to round. Titers
were expressed as the final dilution of serum present in
the serum/virus mixture where 50% of wells are protected.
Preparation of total RNA
Peripheral blood mononuclear cells (PBMCs) isolated
from test swine were seeded in triplicate in 6-well culture
plates at 1 × 107 cells per well in 2 ml of DMEM culture
medium supplemented with 10% FBS and 1% penicillin
and streptomycin. After overnight culture, cells were incu-
bated with 5 μg/ml recombinant VP1 (rVP1), prepared as
described previously [28], or 1 μg/ml of phytohaemagglu-
tinin (PHA; Sigma) for 6 h at 37°C in 5% CO2. Cells stim-
ulated with PHA were used as positive controls. Following
the incubation, cells were lysed in TRIzol™ reagent (Invit-
rogen), and total cellular RNA was isolated according to
the manufacturer's instructions. The concentration of
total cellular RNA was quantified by determination of
optical density at 260 nm. Total cellular RNA was reverse
transcribed into cDNA by SuperScript III™ reverse tran-
scriptase (Invitrogen). The resulting cDNA was amplified
by real-time PCR.
Measurement of IFN-γ production by real-time PCR
Total IFN-γ mRNA was measured by real-time PCR by use
of a SYBR Green system in a LightCycler instrument
(Roche Applied Science). Samples were assayed in a final
volume of 20 μl with use of the FastStart DNA Master
SYBR Green I Kit (Roche), including heat-activatable Taq
polymerase, plus 4 mM MgCl2, each primer (primer
sequences were SW-IFN-γ (F4), 5'-GCTCTGGGAAACT-
GAATGACTTCG; and SW-IFN-γ (R4), 5'- GACTTCTCTTC-
CGCTTTCTTAGGTTAG) at 0.5 μM and 2 μl of cDNA was
prepared as described above. Following polymerase acti-
vation (95°C for 10 min), 40 cycles were run with a 15 s
denaturation at 95°C, 2 s annealing at 60°C, and 15 s
extension at 72°C. The temperature transition rate was
20°C/s for all steps. The amount of PCR product was
measured once every cycle immediately after the 72°C
incubation (extension step) by detection of the fluores-
cence associated with the binding of SYBR Green I to the
amplification product. Fluorescence curves were analyzed
with use of LightCycler software, version 3.0 (RocheAp-
plied Science). The primers were synthesized by Invitro-
gen Life Technologies. For each sample, the amount of
IFN-γ was determined by comparing with a standard curve
and normalized by using β-actin as the internal reference.
All samples were processed in triplicate.
Detection of antibodies against the non-structural protein 
of FMDV
Infected animals produce antibodies to both the structural
and non-structural proteins of FMDV. Therefore, the pres-
ence of antibodies against only structural but not non-
structural proteins can differentiate vaccinated animals
from infected ones [33]. The occurrence of FMDV infec-
tion in swine was determined by measuring elicitation of
antibodies against non-structural 3ABC proteins. Sera
from all groups of swine were collected 8 and 14 days postBMC Biotechnology 2007, 7:62 http://www.biomedcentral.com/1472-6750/7/62
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challenge. The presence of antibodies against the non-
structural protein 3ABC of FMDV in sera were measured
with use of the Ceditest®FMDV-NS strip ELISA kit (Cedi
Diagnostics BV) [33] according to the manufacturer's
instructions.
Results
Characterization of a recombinant infectious pBVP1 
vector
To use a BaMV-based vector to express VP1 epitopes of
FMDV, we first constructed a modified BaMV vector, pBS-
d35CP, derived from a pBaMV-S vector (Fig. 1a) by delet-
ing 35 amino acids from the N-terminal CP and inserting
multiple cloning sites (Fig. 1b). A cDNA sequence corre-
sponding to the FMDV (O/Taiwan/97) VP1 128–164
amino acids was then cloned into the CP truncated region
of pBS-d35CP to generate the pBVP1 vector (Fig. 1c). We
revealed the infectivity of the recombinant viral vector in
both the systemic host N. benthamiana and the local lesion
host C. quinoa. In N. benthamiana, infection with pBVP1
produced milder mosaic symptoms than that with
pBaMV-S, the full-length infectious cDNA of wild-type
BaMV. In C. quinoa, chlorotic local lesions formed after
pBVP1 inoculation were also distinct from those caused
by pBaMV-S.
Detection of VP1 epitopes in plants infected with pBVP1
We then determined whether pBVP1 could infect target
plants to generate BaMV CP containing VP1 epitopes of
FMDV. Total protein samples taken from C. quinoa leaves
inoculated with distilled water (mock), pBaMV-S, pBS-
d35CP or pBVP1 were respectively subjected to SDS-poly-
acrylamide gel electrophoresis (SDS-PAGE; Fig. 2A) and
Western blotting analysis with use of anti-BaMV-S CP
antibodies (Fig. 2B). As anticipated, protein extract of
mock-inoculated leaves showed no BaMV CP (Fig. 2A and
2B, lane 1). The N-terminal truncated CP (Fig. 2A and 2B,
lane 3), detected in the protein extract of pBS-d35CP-
inoculated plants, migrated faster than the wild-type CP
of pBaMV-S-infected plants (Fig. 2A and 2B, lane 2),
which in turns migrated slightly faster than the chimeric
CP from pBVP1 inoculated plants (Fig. 2A and 2B, lane 4).
These results indicate an apparent size difference between
the CP generated from pBVP1 and those from pBaMV-S
and pBS-d35CP.
To further verify that CP generated from pBVP1-inocu-
lated plants contained the VP1 antigenic epitopes of
FMDV, Western blotting analysis with use of rabbit serum
against FMDV VP1 (Fig. 2C) or serum from FMDV-
infected swine (Fig. 2D) was undertaken. Both sera recog-
nized a protein band of 31 kDa corresponding to the chi-
meric CP (Fig. 2C and 2D, lane 4). In contrast, no protein
band was detected in the wild-type CP of BaMV-S (Fig. 2C
and 2D, lane 2) or truncated CP of BS-d35CP (Fig. 2C and
2D, lane 3). Additional immunoblotting studies with the
same antibodies in C. quinoa showed that even after five
subsequent passages, protein extracts of pBVP1-inocu-
lated leaves still contained a major protein band with sim-
ilar mobility to chimeric CP (data not shown). Taken
together, these results suggest that the inoculation of
plants with pBVP1 plasmid generates a fusion protein
comprised of truncated CP of BaMV and the VP1 epitopes
of FMDV.
Expression of FMDV VP1 epitopes on BVP1 virus particles
To further confirm that the FMDV VP1 epitopes was
expressed on the viral surface, the chimeric virus, namely
BVP1, was isolated from pBVP1-infected C. quinoa leaf tis-
sue. The yield of the purified virus was estimated to be
around 0.2–0.5 mg per gram of fresh leaf tissue. The puri-
fied BVP1 virus was analyzed by gel electrophoresis and
silver staining. As shown in Fig. 3, small amounts of virus
samples (5 ng and 50 ng) showed only single major band.
When larger amount of virions (500 ng) was loaded, the
majority of proteins migrated as 31 kD of chimeric CP
while several low molecular weight bands of degraded CP
were detected. The presence of the FMDV VP1 peptide on
the virus surface was subsequently determined by using
anti-BaMV CP or anti-FMDV VP1 antibodies, and the for-
mation of the antibody-antigen complexes was detected
with use of gold-labeled secondary antibodies and immu-
noelectron microscopy. We found that chimeric BVP1 vir-
ions were specifically labeled with anti-BaMV CP and anti-
FMDV VP1 respectively (Fig. 4A and 4B). In contrast,
BaMV-S virions were merely labeled with anti-BaMV CP
serum (data not shown) but not with anti-FMDV VP1
Detection of VP1 antigenic epitopes in Chenopodium quinoa  (C. quinoa) leaves inoculated with chimeric virus BVP1 Figure 2
Detection of VP1 antigenic epitopes in Chenopodium 
quinoa (C. quinoa) leaves inoculated with chimeric 
virus BVP1. Leaves of C. quinoa were mock-inoculated (lane 
1) or inoculated with wild-type pBaMV-S (lane 2), pBS-d35CP 
(lane 3) or pBVP1 (lane 4). Total proteins were prepared as 
described in Methods and electrophoretically separated on a 
12% SDS-polyacrylamide gel, stained with Coomassie blue 
(panel A), or transferred to PVDF membrane, and detected 
with anti-BaMV-S CP serum (panel B), rabbit anti-FMDV VP1 
serum (panel C), or serum from FMDV-infected swine (panel 
D).BMC Biotechnology 2007, 7:62 http://www.biomedcentral.com/1472-6750/7/62
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(Fig. 4C). By negatively staining, no difference in mor-
phology could be observed between wild type BaMV and
chimeric virus BVP1. These data indicate that the FMDV
VP1 peptide is fused to BaMV CP and expressed on the
viral surface.
Antibody responses elicited by chimeric virus BVP1 in swine
We then evaluated the ability of this chimeric virus to trig-
ger immunity against FMDV in swine. In our first experi-
ment, two groups of three pigs each were given
intramuscular injections of 5 mg and 10 mg of BVP1 chi-
meric virus respectively and boosted with similar amount
of BVP1 6 weeks later. Another two groups of two pigs
each were vaccinated with 5 mg BaMV-S wild-type virus or
PBS buffer respectively as negative controls. Sera obtained
from both 5 mg and 10 mg BVP1-immunized swine elic-
ited high levels of anti-VP1 antibodies, as measured by
ELISA. In contrast, swine immunized with BaMV-S or PBS
buffer all showed little, if any, anti-VP1 antibodies (Fig.
5). Furthermore, neutralizing antibodies (NAs) were
detected in the sera of the BVP1-vaccinated groups but not
in those of the negative control groups (Table 1). To con-
firm that even smaller amounts of BVP1 could exhibit
similar effects, we immunized swine with either 0.5 mg or
1 mg of BVP1 and boosted with similar amounts of BVP1
4 weeks later. Substantial titers of anti-VP1 antibodies
(Fig. 5) and NAs (Table 1) were detected even in the sera
of swine given one inoculation of 0.5 mg BVP1, indicating
that the chimeric BVP1 virus can effectively trigger specific
NAs in swine.
IFN-γ production in immunized swine
To evaluate whether BVP1-immunized swine could
induce a cell-mediated immune response in addition to
NAs (a humoral response), we analyzed the ability of
PBMCs to produce IFN-γ, a cytokine that plays an impor-
tant role in cell-mediated immune responses. Real-time
PCR analysis of specific IFN-γ mRNA showed that upon
VP1 antigen stimulation, PBMCs from BVP1-immunized
swine induced production of IFN-γ whereas BaMV-S or
PBS-immunized swine did not (Table 2). As control,
PBMCs from all groups of swine were stimulated with T-
cell mitogen PHA (1 μg/ml) and found to produce similar
amounts of IFN-γ (Table 2).
Protection against FMDV challenge in immunized swine
We then determined whether BVP1 could confer immu-
noprotection in swine. All groups of swine were chal-
lenged with 105.0 TCID50 (50% tissue culture infective
dose) of FMDV (O/Taiwan/97) and monitored for the
appearance of FMD symptoms for two weeks. At days 2–4
after challenge, the negative control groups showed seri-
ous symptoms of FMD. In contrast, all swine immunized
with BVP1 showed no FMD symptoms after challenge. In
addition, since infected animals produce antibodies to
both the structural and non-structural proteins of FMDV,
the presence of antibodies against only structural but not
non-structural proteins can differentiate vaccinated ani-
mals from infected ones [33]. We thus examined the pres-
ence of FMDV in sera of all animals 8–14 days after FMDV
challenge by measuring antibodies against non-structural
protein 3ABC. All the groups immunized with BVP1 did
not develop an antibody response to 3ABC while control
groups became 3ABC positive (Table 3).
Discussion
Although use of CPMV and TMV as a vector to generate
chimeric plant virus-derived vaccines against FMD has
been described [14-16], effort is needed to improve not
only the stability of such chimeric viruses but also the
immune responses and protection they induce in the tar-
get animals [17]. Recently developed was a modified
TMV-based vector that allows for the expression of pep-
Analysis of purified BVP1 virions on SDS- PAGE Figure 3
Analysis of purified BVP1 virions on SDS- PAGE. Vari-
ous amounts of BVP1 virions purified from infected leaves by 
CsCl2 density gradient centrifugation were analyzed by elec-
trophoresis through a 12.5% polyacrylamide and stained with 
PlusOne Silver Staining Kit (Amersham Bioscience, Sweden). 
Lane M, molecular weight standards. The relative molecular 
weights were as indicated on the left.BMC Biotechnology 2007, 7:62 http://www.biomedcentral.com/1472-6750/7/62
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tides as long as 25 amino acids. Such chimeric constructs,
however, are not as effective as the TMV expressing the 11
amino acid epitope in generating protective immunity
[34]. In this study, we infected plants with plasmid pBVP1
to generate a chimeric virion (BVP1) expressing a 37
amino acid peptide of VP1 and elicited strong immunity
in swine even after just one inoculation (Table 1 and Fig.
5). The BaMV-based expression system therefore may be
better than the TMV system in expressing peptides up to
37 amino acids or longer. However, as different trans-
genes were used in BaMV, CPMV and TMV, it is difficult to
judge at present whether chimeric BaMV is better than chi-
meric CPMV and TMV in terms of their elicitation of
immune responses.
The prominent G-H loop of the capsid protein VP1 of
FMDV, including at its apex a highly conserved Arg-Gly-
Asp (RGD) tripeptide, has been identified as a major B-
cell epitope for eliciting NAs [8-11]. However, administer-
ing G-H loop synthetic peptides alone in cattle and swine
has resulted in limited induction of NAs or ineffective pro-
tection [35]. Piatti and others [36] showed induction of
both T-cell immunity and high NA response positively
correlated with effective protection in experimental ani-
mals immunized with inactivated FMDV. Parida and
coauthors [37] have thus suggested that evaluation of
effective protection of FMD vaccine should combine the
presence of NAs and IFN-γ production (an indicator of
cell-mediated immunity). Because the VP1 sequence (res-
idues 135–160) of FMDV O1 Campos contains not only
the G-H loop, the major B-cell epitope, but also the
immunodominant T epitopes [38-40], in this study, we
introduced residues 128–164, which includes T and B
epitopes, of the VP1 sequence into the BaMV-based vec-
tor. Swine immunized with BVP1 elicited VP1-specific
IFN-γ and high titers of NA against FMDV (Tables 1 and
2). To our knowledge, this is the first report of a chimeric
plant virus correctly expressing VP1 epitope(s) to properly
induce both humoral (as indicated by NAs) and cell-
mediated immune responses (as indicated by VP1-specific
IFN-γ production).
Most importantly, our results have clearly demonstrated
that BVP1 immunization can protect swine against a chal-
lenge of 105.0 TCID50 FMDV, an amount 10 times higher
than that recommended by the World Organization for
Animal Health [32]. In addition, we have recently exam-
ined whether one inoculation is sufficient to protect the
animals. Our preliminary results revealed that swine
immunized once with 1 mg BVP1 were protected from
FMDV challenge. We thus propose that BVP1 may be
superior to other plant viruses such as TMV in presenting
the VP1 peptide so that the immunogenic site(s) of the
peptide mimic the conformation of the major antigenic
epitope(s) of FMDV, thereby generating high titers of NAs
as well as cellular immune responses. More studies involv-
ing the incorporation of the similar transgene into TMV
and evaluation of the optimal dosage for protection, how-
ever, must be undertaken to confirm this proposal. Of
note, an important advantage of the BaMV-based vector
Immunoelectron microscopy for identification of BaMV CP and FMDV VP1 on the surface of virus particles Figure 4
Immunoelectron microscopy for identification of BaMV CP and FMDV VP1 on the surface of virus particles. 
Leaf dips from C. quinoa infected with pBVP1 (A, B) or pBaMV-S (C) were obtained 10 days post-inoculation. Grids were first 
incubated with leaf extract and coated with diluted anti-BaMV CP serum (A) or anti-FMDV VP1 serum (B, C) followed by gold-
labeled goat anti-rabbit IgG complexes. Grids were inspected in a Philips CM100 electron microscope. All bars represent 250 
nm.BMC Biotechnology 2007, 7:62 http://www.biomedcentral.com/1472-6750/7/62
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over CPMV, TMV and most other plant virus-based vectors
is that BaMV is not a pathogen for a variety of crops and
therefore may be ecologically safer for field use [23].
Conclusion
We have inserted a transgene encoding a partial sequence
of the capsid VP1 of FMDV in the plant virus BaMV. The
recombinant plasmid could infect host plants to generate
chimeric virions that elicit significant NA titers in the ani-
mals even after just one inoculation. The capability of this
BaMV-based vector to carry larger transgenes, effectively
express foreign peptide epitope(s) and induce protective
humoral and cellular immune responses would be advan-
tageous for its application in the development of vaccines
against not only FMDV but also many other pathogens.
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Table 1: Titers of neutralizing antibodies (NAs) in swine immunized with chimeric virus BVP1
Experiment 1
NA titers a
Antigens Swine No. 4W 6W 10W
10 mg BVP1 858 8 64 11
859 11 362 362
860 16 256 256
5 mg BVP1 861 6 32 23
862 91 362 512
863 64 256 256
5 mg BaMV-S 864 –––
865 –––
PBS 866 –––
867 –––
Experiment 2
NA titers a
Antigens Swine No. 3W 4W 5W
5  m g  B V P 1 148 1 1
2 32 128 128
3 1 66 44 5
1 mg BVP1 4 16 32 256
54 1 6 2 3
6 3 23 23 2
0.5 mg BVP1 7 8 64 91
8 – 83 2
9 8 16 181
5 mg BaMV-S 10 –––
11 –––
PBS 12 –––
13 –––
a The titer of NAs from each swine was measured at indicated weeks as described in Methods. (-) means that no NAs were detected at the highest 
concentration tested.BMC Biotechnology 2007, 7:62 http://www.biomedcentral.com/1472-6750/7/62
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Table 2: IFN-γ production and protection in swine immunized with chimeric virus BVP1
IFN-γ (fold change)a
Antigens Swine No. rVP1 PHA Clinical symptomsb
10 mg BVP1 858 3.8 2.4 No
859 4.1 2.8 No
860 3.4 2.2 No
5 mg BVP1 861 3.1 2.9 No
862 3.8 2.1 No
863 2.4 2.6 No
5 mg BaMV-S 864 1.0 2.5 Yes
865 1.1 2.2 Yes
PBS 866 1.0 2.6 Yes
867 1.0 2.4 Yes
a PBMCs isolated from swine 10 weeks after priming were stimulated with 5 μg/ml of rVP1 or 1 μg/ml of PHA for 6 h at 37°C. Total cellular RNA 
was then extracted for the assay of IFN-γ production by real-time PCR. The fold change was determined by dividing the quantity of specific IFN-γ 
mRNA from stimulated cells by the quantity of IFN-γ mRNA from the unstimulated cells.
b Swine of all groups were challenged with FMDV (O/Taiwan/97) and monitored daily for clinical symptoms of FMD for 14 days as described in 
Methods.
Serum titers of swine immunized with chimeric virus BVP1 Figure 5
Serum titers of swine immunized with chimeric virus 
BVP1. Groups of swine were immunized with 0.5 mg (▲), 5 
mg (), 10 mg (■) of chimeric virus BVP1 or 5 mg of wild-
type virus BaMV-S (❍) or PBS (). Swine sera were collected 
at the indicated time after immunization. Anti-VP1 titers 
were determined by ELISA. The animals inoculated with 0.5 
mg BVP1 were boosted with the same amount of BVP1 four 
weeks after priming while those inoculated with 5 mg and 10 
mg of BVP1 were boosted six weeks after priming.BMC Biotechnology 2007, 7:62 http://www.biomedcentral.com/1472-6750/7/62
Page 10 of 11
(page number not for citation purposes)
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